Ron Kerstens schreef op 23 februari 2022 15:54:
Zelfde persbericht (ook well tolerated:-) ) als ProQR, zelfde koersklap (van 50 dollar naar 11 dollar);
Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration
February 23, 2022 at 6:00 AM EST
- The study did not meet the primary endpoint of showing non-inferior visual acuity gains compared to aflibercept given every eight weeks
- Nearly 60% of KSI-301 patients achieved every 5-month dosing at year 1 with visual acuity gains and anatomic improvements comparable to the overall aflibercept group
- KSI-301 was safe and well tolerated, with no new or unexpected safety signals